STAT+: Servier’s $1.55 billion muscular dystrophy drug fails first major test

Servier reports a surprise setback for a drug being tested for a form of muscular dystrophy that lacks treatment.

How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →

Every article behind this summary — 1 article from 1 outlet